200,000+ products from a single source!
sales@angenechem.com
1622-79-3 | 1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-, hydrochloride (1:1)
CAS No: 1622-79-3 Catalog No: AG001SVX MDL No:MFCD00270922
Product Description
Catalog Number:
AG001SVX
Chemical Name:
1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-, hydrochloride (1:1)
CAS Number:
1622-79-3
Molecular Formula:
C16H23ClFNO
Molecular Weight:
299.8113
MDL Number:
MFCD00270922
IUPAC Name:
1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one;hydrochloride
InChI:
InChI=1S/C16H22FNO.ClH/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14;/h4-7,13H,2-3,8-12H2,1H3;1H
InChI Key:
MQHYXXIJLKFQGY-UHFFFAOYSA-N
SMILES:
CC1CCN(CC1)CCCC(=O)c1ccc(cc1)F.Cl
EC Number:
216-599-9
UNII:
88G640374K
NSC Number:
760102
Properties
Complexity:
279
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
299.145g/mol
Formal Charge:
0
Heavy Atom Count:
20
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
299.814g/mol
Monoisotopic Mass:
299.145g/mol
Rotatable Bond Count:
5
Topological Polar Surface Area:
20.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Development of orally disintegrating tablets comprising controlled-release multiparticulate beads. | Drug development and industrial pharmacy 20121101 |
| Melperone is ineffective in treating Parkinson's disease psychosis. | Movement disorders : official journal of the Movement Disorder Society 20120501 |
| Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia. | TheScientificWorldJournal 20120101 |
| Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. | Psychiatry research 20100430 |
| Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. | Human psychopharmacology 20090701 |
| Diminished glucocorticoid negative feedback in polydipsic hyponatremic schizophrenic patients. | The Journal of clinical endocrinology and metabolism 20070201 |
| Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. | European journal of clinical pharmacology 20060401 |
| Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. | European journal of medicinal chemistry 20050201 |
| P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. | Journal of psychopharmacology (Oxford, England) 20041201 |
| Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. | Pharmacology, biochemistry, and behavior 20040201 |
| [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients]. | MMW Fortschritte der Medizin 20031009 |
| A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. | Schizophrenia research 20030701 |
| The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. | Schizophrenia research 20030101 |
| Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. | Pharmacopsychiatry 20030101 |
| Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. | Brain research 20021129 |
| [Atypical neuroleptics in dementia. Managing behavioral disorders early and efficiently]. | MMW Fortschritte der Medizin 20020307 |
| Melperone in the treatment of neuroleptic-resistant schizophrenia. | Psychiatry research 20011231 |
| [Practical experiences in the therapy of postweaning edema disease in piglets]. | Berliner und Munchener tierarztliche Wochenschrift 19961001 |
| Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. | European journal of pharmacology 19930604 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.